Pulmonary embolism in patients with severe COVID-19 treated with intermediate- to full-dose enoxaparin: A retrospective study



  • Cleante Scarduelli | cleante@libero.it ASST Mantova, Italy. https://orcid.org/0000-0003-3600-7653
  • Francesco Inglese ASST Mantova Italy, Italy. https://orcid.org/0000-0001-6467-8820
  • Massimiliano Beccaria Pulmonology and Respiratory Intensive Care Unit ASST Mantova , Italy. https://orcid.org/0000-0002-0901-4981
  • Fabio Speafico Pulmonology and Respiratory Intensive Care Unit ASST Mantova, Italy.
  • Martina Garuti Pulmonology and Respiratory Intensive Care Unit ASST Mantova, Italy.
  • Antonietta Pecoriello Pulmonology and Respiratory Intensive Care Unit ASST Mantova, Italy.
  • Giulia Cervi Pulmonology and Respiratory Intensive Care Unit ASST Mantova, Italy.
  • Graziana Greco Pulmonology and Respiratory Intensive Care Unit ASST Mantova, Italy. https://orcid.org/0000-0003-2887-0756
  • Sara Scarduelli Internal Medicine Department of Medical and Surgical Sciences Bologna University , Italy.
  • Giuseppe Lucchini Bio-statistical Service, ASST, Mantova, Italy.
  • Giuseppe De Donno Pulmonology and Respiratory Intensive Care Unit ASST Mantova, Italy.
  • Claudio Borghi Internal Medicine Department of Medical and Surgical Sciences Bologna University, Italy.


Coronavirus disease (COVID-19) may predispose patients to pulmonary embolism (PE), despite standard thromboprophylaxis. Our retrospective study aimed to report the prevalence of PE in patients with COVID-19 and severe respiratory failure (SRF) treated with intermediate- to full-dose enoxaparin. We analyzed data from patients with COVID-19 pneumonia and SRF admitted to our Respiratory Intensive Care Unit (RICU) from February 27 to April 20, 2020. All patients received at least intermediate-dose enoxaparin (40 mg twice daily). Computed tomography pulmonary angiography (CTPA) was used to detect PE. Ninety-two patients with COVID-19 pneumonia and SRF were admitted to our RICU. Twenty-two patients underwent CTPA (24 %), 11 of whom had PEs (12%). We hypothesize that the enoxaparin treatment may be responsible for the lower prevalence of PE as compared to previous reports of similar patients, even if our report had several limitations, mainly the small sample size.



PlumX Metrics


Download data is not yet available.


Guan WJ, Ni ZY, Yu H, et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Eng J Med 2020;382:1708–1720. DOI: https://doi.org/10.1056/NEJMoa2002032

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. DOI: https://doi.org/10.1016/S0140-6736(20)30183-5

Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–513. DOI: https://doi.org/10.1016/S0140-6736(20)30211-7

Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–1069. DOI: https://doi.org/10.1001/jama.2020.1585

Ministero Della Salute. Covid-19, i casi in Italia il 18 dicembre: situazione Italia al 18 Dicembre. Accessed December 18 2020. http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=4539

Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844–847. DOI: https://doi.org/10.1111/jth.14768

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18:1094–1099. DOI: https://doi.org/10.1111/jth.14817

Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Eng J Med. 2020;382:e38. DOI: https://doi.org/10.1056/NEJMc2007575

Klok FA, Kruip MJ, Van der Meer NJ, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–7. DOI: https://doi.org/10.1016/j.thromres.2020.04.013

Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18:1421–24. DOI: https://doi.org/10.1111/jth.14830

Piazza G, Campia U, Hurwitz S, et al. Registry of arterial and venous thromboembolic complications in patients with COVID-19. JACC 2020;76:2060–72. DOI: https://doi.org/10.1016/j.jacc.2020.08.070

Poissy J, Goutay J, Caplan M, et al; Lille ICU Haemostasis COVID-19 Group. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation. 2020;142:184–6. DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.047430

Lodigiani C, Iapichino G, Carenzo L, et al; Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14. DOI: https://doi.org/10.1016/j.thromres.2020.04.024

World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases: interim guidance. Accessed 10 August 2020. https://www.who.int/publications/i/item/10665-331501

Kresoja KP, Ebner M, Rogge NI, et al. Prediction and prognostic importance of in-hospital major bleeding in a real-world cohort of patients with pulmonary embolism. Int J Cardiol. 2019;290:144–9. DOI: https://doi.org/10.1016/j.ijcard.2019.03.017

Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71:762–8. DOI: https://doi.org/10.1093/cid/ciaa248

Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Eng J Med 2020;383:120–8. DOI: https://doi.org/10.1056/NEJMoa2015432

Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endothelitis in COVID-19. Lancet 2020;395:417–8. DOI: https://doi.org/10.1016/S0140-6736(20)30937-5

Wichmann D, Sperhake JP, Lutgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med 2020;173:268–7. DOI: https://doi.org/10.7326/M20-2003

Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic and thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-art review. J Am Coll Cardiol 2020;75:2950–73. DOI: https://doi.org/10.1016/j.jacc.2020.04.031

Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307:2526–33.

Simonnet A, Chetboun M, Poissy J, et al; the LICORN and the Lille COVID-19 and Obesity Study Group. High prevalence of obesity in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) 2020;28:1195–9. DOI: https://doi.org/10.1002/oby.22831

British Thoracic Society. BTS Guidance on venous thromboembolic disease in patients with COVID-19. Accessed 10 August 2020. https://brit-thoracic.org.uk/document-library/quality-improvement/covid-19/bts-guidance-on-venous-thromboembolic-disease-in-patients-with-covid-19

Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020;41:543-603. DOI: https://doi.org/10.1093/eurheartj/ehz405

National Institutes of Health (NIH). Coronavirus disease 2019 (COVID-19) treatment guidelines. Accessed December 12, 2020. https://www.covid19treatmentguidelines.nih.gov/


Pneumology - Original Articles
pulmonary embolism, venous thromboembolism, COVID-19, enoxaparin, respiratory failure
  • Abstract views: 285

  • PDF: 276
How to Cite
Scarduelli, Cleante, Francesco Inglese, Massimiliano Beccaria, Fabio Speafico, Martina Garuti, Antonietta Pecoriello, Giulia Cervi, Graziana Greco, Sara Scarduelli, Giuseppe Lucchini, Giuseppe De Donno, and Claudio Borghi. 2021. “Pulmonary Embolism in Patients With Severe COVID-19 Treated With Intermediate- to Full-Dose Enoxaparin: A Retrospective Study”. Monaldi Archives for Chest Disease, March. https://doi.org/10.4081/monaldi.2021.1758.